[go: up one dir, main page]

WO2001064240A3 - Methods for promoting production of myelin by schwann cells - Google Patents

Methods for promoting production of myelin by schwann cells Download PDF

Info

Publication number
WO2001064240A3
WO2001064240A3 PCT/US2001/006294 US0106294W WO0164240A3 WO 2001064240 A3 WO2001064240 A3 WO 2001064240A3 US 0106294 W US0106294 W US 0106294W WO 0164240 A3 WO0164240 A3 WO 0164240A3
Authority
WO
WIPO (PCT)
Prior art keywords
myelin
schwann cells
methods
zcyto7
promoting production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/006294
Other languages
French (fr)
Other versions
WO2001064240A2 (en
Inventor
Emma E Moore
Julia E Novak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Priority to JP2001563137A priority Critical patent/JP2003525251A/en
Priority to AU2001241816A priority patent/AU2001241816A1/en
Priority to CA002401716A priority patent/CA2401716A1/en
Priority to EP01913120A priority patent/EP1259253A2/en
Publication of WO2001064240A2 publication Critical patent/WO2001064240A2/en
Publication of WO2001064240A3 publication Critical patent/WO2001064240A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A method for promoting the expression of myelin or Protein Zero in Schwann cells using Zcyto7 or IL-17. Zcyto7 or IL-17 are further used to promote myelination of the peripheral nervous system. This is particularly useful in treating diseases dymyelinating diseases such as diabetic neuropathy, Guillain-Barre' Syndrome, chronic demyelinating disease, acute demyelinating polyneuropathy and human immunodeficiency viral demyelinating neuropathy or demyelination caused by trauma.
PCT/US2001/006294 2000-02-29 2001-02-27 Methods for promoting production of myelin by schwann cells Ceased WO2001064240A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001563137A JP2003525251A (en) 2000-02-29 2001-02-27 Method for promoting myelin production by Schwann cells
AU2001241816A AU2001241816A1 (en) 2000-02-29 2001-02-27 Methods for promoting production of myelin by schwann cells
CA002401716A CA2401716A1 (en) 2000-02-29 2001-02-27 Methods for promoting production of myelin by schwann cells
EP01913120A EP1259253A2 (en) 2000-02-29 2001-02-27 Methods for promoting production of myelin by schwann cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51522300A 2000-02-29 2000-02-29
US09/515,223 2000-02-29

Publications (2)

Publication Number Publication Date
WO2001064240A2 WO2001064240A2 (en) 2001-09-07
WO2001064240A3 true WO2001064240A3 (en) 2002-02-21

Family

ID=24050447

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/006294 Ceased WO2001064240A2 (en) 2000-02-29 2001-02-27 Methods for promoting production of myelin by schwann cells

Country Status (5)

Country Link
EP (1) EP1259253A2 (en)
JP (1) JP2003525251A (en)
AU (1) AU2001241816A1 (en)
CA (1) CA2401716A1 (en)
WO (1) WO2001064240A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1379278A4 (en) * 2001-03-26 2004-08-11 Zymogenetics Inc METHOD FOR INDUCING THE PROLIFERATION OF RETINAL STEM CELLS
WO2008073653A2 (en) * 2006-11-08 2008-06-19 Zymogenetics, Inc. Il- 17b for use in wound healing
EP3191108A4 (en) * 2014-09-12 2018-06-27 The Administrators of the Tulane Educational Fund Neural microphysiological systems and methods of using the same
KR102617833B1 (en) 2016-05-06 2023-12-27 엑시큐어 오퍼레이팅 컴퍼니 Liposomal spherical nucleic acid (SNA) construct presenting antisense oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor mRNA
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
CN120392966B (en) * 2025-07-01 2025-10-21 华中科技大学同济医学院附属协和医院 Targeted drugs for the treatment of diabetic peripheral neuropathy and neuroprotective drugs that regulate Schwann cell proliferation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
WO1998049310A1 (en) * 1997-04-25 1998-11-05 Zymogenetics, Inc. Mammalian cytokine-like factor 7
WO1999003982A1 (en) * 1997-07-16 1999-01-28 Human Genome Sciences, Inc. Interleukin-20
WO2000073452A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2001046420A2 (en) * 1999-12-23 2001-06-28 Genentech, Inc. Il-17 and il-17r homologous polypeptides and therapeutic uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE295414T1 (en) * 1995-07-19 2005-05-15 Inst Genetics Llc HUMAN CTLA-8 AND USE OF CTLA-8 SIMILAR PROTEINS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
WO1998049310A1 (en) * 1997-04-25 1998-11-05 Zymogenetics, Inc. Mammalian cytokine-like factor 7
WO1999003982A1 (en) * 1997-07-16 1999-01-28 Human Genome Sciences, Inc. Interleukin-20
WO2000073452A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2001046420A2 (en) * 1999-12-23 2001-06-28 Genentech, Inc. Il-17 and il-17r homologous polypeptides and therapeutic uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DUNCAN IAN D ET AL: "Repair of myelin disease: Strategies and progress in animal models.", MOLECULAR MEDICINE TODAY, vol. 3, no. 12, December 1997 (1997-12-01), pages 554 - 561, XP001024164, ISSN: 1357-4310 *

Also Published As

Publication number Publication date
EP1259253A2 (en) 2002-11-27
WO2001064240A2 (en) 2001-09-07
CA2401716A1 (en) 2001-09-07
AU2001241816A1 (en) 2001-09-12
JP2003525251A (en) 2003-08-26

Similar Documents

Publication Publication Date Title
NO905264L (en) PROCEDURE FOR THE MANUFACTURE OF BIOLOGICAL ACTIVE PROTEIN
WO1994024160A3 (en) Erythropoietin muteins with enhanced activity
BR9106826A (en) OLIGONUCLEOTIDEO OR ANALOG OF OLIGONUCLEOTIDEO, PROCESS TO MODULATE THE PRODUCTION OF A PROTEIN BY AN ORGANISM, TO TREAT AN ORGANISM AND PROCESSES TO SYNTHESIZE: 9 (2'-DEOXI-2'-SUBSTITUTED-BETA-D-RIBOFURANI -DESOXY-2'-FLUOR-BETA-D-RIBOFURANOSYL) -GUANINE
NZ543467A (en) The severe acute respiratory syndrome coronavirus
WO1995021919A3 (en) Protein having tpo activity
WO2003032994A3 (en) Novel tri-substituted pyrimidines, method for production and use thereof as medicament
ATE324884T1 (en) USE OF GAMMA-LINOLENIC ACID OR DIHOMOGAMMALINOLENIC ACID IN THE PRODUCTION OF A MEDICATION FOR THE TREATMENT OF HUNTINGTON'S CHOREA
BRPI0417959A (en) antibody or functional fragment thereof, pharmaceutical composition, method for treating or prophylaxis of stroke and other neurological disorders / disorders in a human, use of an anti-goat antibody, and methods for inhibiting neurodegeneration and / or promoting recovery function in a human patient, to promote axonal growth, to produce an antifungal antibody and to produce an intravenously administered pharmaceutical composition
BR9509001A (en) Protein that targets HIV virions based on HIV-1 VPR fusion molecules
AU4727889A (en) A novel purified thrombomodulin-like glycoprotein obtained from urine.
DE60326450D1 (en) PROCESS FOR PREPARING TOTAL SALVIANOLIC ACID
ATE307203T1 (en) USE OF AN ANTI-INTERLEUKIN-9 ANTIBODY FOR PRODUCING A MEDICATION FOR THE TREATMENT OF ASTHMA
WO2001064240A3 (en) Methods for promoting production of myelin by schwann cells
HUT58037A (en) Process for producing n-2,3-butadienyl tri- and tetraaminoalkane derivatives
AU1711292A (en) Methods and compositions of a preparation and use of a herpes protease
EP1969003B8 (en) Uses of a NEUROTROPHIC FACTOR PROTEIN
ATA145488A (en) USE OF THE ENZYME COFACTOR NADPH IN THE PRODUCTION OF A MEDICINAL PRODUCT
WO1997003204A3 (en) (s)-hydroxynitrillyase from hevea brasiliensis
WO2004043373A3 (en) Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
ATE201601T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A NEUTRALIZED VIRUS AND USE THEREOF
WO2004058268A3 (en) Use of von tetrahydrobiopterine derivatives in the treatment and nutrition of patients with amino acid metabolic disorders
BG102707A (en) NEW TRIAZOLOPURINES, METHOD FOR THEIR RECOVERY AND THEIR APPLICATION AS MEDICINES
WO2006041409A8 (en) Medical solution, method for producing and use thereof
FR2610633B1 (en) PROCESS FOR OBTAINING A 1-ANTITRYPSIN CONCENTRATE FROM HUMAN PLASMA AND THE USE THEREOF AS A MEDICAMENT
PL373004A1 (en) Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 563137

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2401716

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001913120

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001913120

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642